Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban vs Enoxaparin in Elective Total Knee Replacement
NCT00452530Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial of apixaban in deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths at Day 14. Started Jun 2007; status: completed.
02
Drugs
apixaban
03
Conditions
deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT00452530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452530.